Weishaupt, C., & Schneider, S. W. (2016). Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. The lancet. Haematology, 3(2), . https://doi.org/10.1016/S2352-3026(15)00251-3
Chicago-Zitierstil (17. Ausg.)Weishaupt, Carsten, und Stefan W. Schneider. "Anticoagulation with Rivaroxaban for Livedoid Vasculopathy (RILIVA): A Multicentre, Single-arm, Open-label, Phase 2a, Proof-of-concept Trial." The Lancet. Haematology 3, no. 2 (2016). https://doi.org/10.1016/S2352-3026(15)00251-3.
MLA-Zitierstil (9. Ausg.)Weishaupt, Carsten, und Stefan W. Schneider. "Anticoagulation with Rivaroxaban for Livedoid Vasculopathy (RILIVA): A Multicentre, Single-arm, Open-label, Phase 2a, Proof-of-concept Trial." The Lancet. Haematology, vol. 3, no. 2, 2016, https://doi.org/10.1016/S2352-3026(15)00251-3.